Superworth10x Genomics price to free cash flow TXG
Market value divided by free cash flow over the last twelve months, since 2024.
- Today, Oct 23, 2026
- 76.8×
- Peer median
- 26.4×
10x Genomics' price to free cash flow is 76.8× as of Oct 23, 2026.
The median for 10 diagnostics and research stocks of a similar size is 26.4×.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 76.8× | 17.8× | 100× |
| 2025 | 25.6× | 22.2× | 72.5× |
| 2024 | 67.8× | 62.0× | 75.9× |
Against its peers
Companies in Medical - Diagnostics & Research nearest 10x Genomics' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| TXG10x Genomics | 76.8× |
| CAICaris Life Sciences | 73.0× |
| BIOBio-Rad Laboratories | 28.0× |
| LNTHLantheus | 16.8× |
| BLLNBillionToOne | 153× |
| RVTYRevvity | 31.7× |
| MEDPMedpace | 26.4× |
| VCYTVeracyte | 23.2× |
| CDNACareDx | n/m |
| LHLabcorp | 23.1× |
| DGXQuest Diagnostics | 19.8× |
| Peer median | 26.4× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on 10x Genomics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.